Arcutis Biotherapeutics, Inc.
ARQT
$13.01
$0.050.39%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -140.04M | -195.54M | -198.76M | -217.42M | -262.14M |
| Total Depreciation and Amortization | 2.60M | 2.53M | 1.48M | 1.52M | 1.52M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 40.36M | 38.46M | 38.81M | 37.53M | 37.06M |
| Change in Net Operating Assets | -15.08M | -13.10M | -18.48M | -19.94M | -23.50M |
| Cash from Operations | -112.16M | -167.65M | -176.95M | -198.32M | -247.06M |
| Capital Expenditure | -143.00K | -149.00K | -70.00K | -346.00K | -428.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 28.96M | -68.09M | -107.40M | 44.13M | 180.66M |
| Cash from Investing | 28.82M | -68.24M | -107.47M | 43.78M | 180.23M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -100.00M | -- | -- | -- | -- |
| Issuance of Common Stock | 166.20M | 262.90M | 263.38M | 262.99M | 101.32M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 66.20M | 262.90M | 263.38M | 262.99M | 101.32M |
| Foreign Exchange rate Adjustments | -235.00K | 67.00K | -106.00K | -71.00K | -50.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -17.37M | 27.07M | -21.15M | 108.38M | 34.45M |